Related references
Note: Only part of the references are listed.Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
Aaron S. Mansfield et al.
CLINICAL CANCER RESEARCH (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
Jin Sheng et al.
SCIENTIFIC REPORTS (2016)
Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)
Luis Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer In what state is this art?
Keith M. Kerr et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
The Immune Score as a New Possible Approach for the Classification of Cancer
Jerome Galon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Automated subcellular localization and quantification of protein expression in tissue microarrays
RL Camp et al.
NATURE MEDICINE (2002)
Share Paper
